Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Apathy as a feature of prodromal Alzheimer's disease: an FDG-PET ADNI study.

Delrieu J, Desmidt T, Camus V, Sourdet S, Boutoleau-Bretonnière C, Mullin E, Vellas B, Payoux P, Lebouvier T; Alzheimer's Disease Neuroimaging Initiative.

Int J Geriatr Psychiatry. 2015 May;30(5):470-7. doi: 10.1002/gps.4161. Epub 2014 Jun 20.

PMID:
24953008
2.

Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease?

Teipel S, Grothe MJ; Alzheimer´s Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):526-36. doi: 10.1007/s00259-015-3222-3. Epub 2015 Nov 10.

PMID:
26555082
3.

Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum.

Roy K, Pepin LC, Philiossaint M, Lorius N, Becker JA, Locascio JJ, Rentz DM, Sperling RA, Johnson KA, Marshall GA.

J Alzheimers Dis. 2014;42(1):291-300. doi: 10.3233/JAD-131796.

4.

Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.

Lange C, Suppa P, Frings L, Brenner W, Spies L, Buchert R.

J Alzheimers Dis. 2016;49(4):945-59. doi: 10.3233/JAD-150814.

PMID:
26577523
5.

Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.

Xu L, Wu X, Li R, Chen K, Long Z, Zhang J, Guo X, Yao L; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2016;51(4):1045-56. doi: 10.3233/JAD-151010.

PMID:
26923024
6.

Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.

Trzepacz PT, Yu P, Sun J, Schuh K, Case M, Witte MM, Hochstetler H, Hake A; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2014 Jan;35(1):143-51. doi: 10.1016/j.neurobiolaging.2013.06.018. Epub 2013 Aug 15.

PMID:
23954175
7.

Precuneus and Cingulate Cortex Atrophy and Hypometabolism in Patients with Alzheimer's Disease and Mild Cognitive Impairment: MRI and (18)F-FDG PET Quantitative Analysis Using FreeSurfer.

Bailly M, Destrieux C, Hommet C, Mondon K, Cottier JP, Beaufils E, Vierron E, Vercouillie J, Ibazizene M, Voisin T, Payoux P, Barré L, Camus V, Guilloteau D, Ribeiro MJ.

Biomed Res Int. 2015;2015:583931. doi: 10.1155/2015/583931. Epub 2015 Jun 17.

8.

Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.

Hatashita S, Yamasaki H.

PLoS One. 2013 Jun 14;8(6):e66877. doi: 10.1371/journal.pone.0066877. Print 2013.

9.

Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia.

Arbizu J, Prieto E, Martínez-Lage P, Martí-Climent JM, García-Granero M, Lamet I, Pastor P, Riverol M, Gómez-Isla MT, Peñuelas I, Richter JA, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1394-405. doi: 10.1007/s00259-013-2458-z. Epub 2013 May 29.

PMID:
23715905
10.

Apathy is associated with increased amyloid burden in mild cognitive impairment.

Marshall GA, Donovan NJ, Lorius N, Gidicsin CM, Maye J, Pepin LC, Becker JA, Amariglio RE, Rentz DM, Sperling RA, Johnson KA.

J Neuropsychiatry Clin Neurosci. 2013 Fall;25(4):302-7. doi: 10.1176/appi.neuropsych.12060156.

11.

Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.

Carter SF, Schöll M, Almkvist O, Wall A, Engler H, Långström B, Nordberg A.

J Nucl Med. 2012 Jan;53(1):37-46. doi: 10.2967/jnumed.110.087031.

12.

Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease.

Habeck C, Risacher S, Lee GJ, Glymour MM, Mormino E, Mukherjee S, Kim S, Nho K, DeCarli C, Saykin AJ, Crane PK; Alzheimer’s Disease Neuroimaging Initiative.

Brain Imaging Behav. 2012 Dec;6(4):568-83. doi: 10.1007/s11682-012-9208-x.

13.

Visual rating and volumetric measurement of medial temporal atrophy in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort: baseline diagnosis and the prediction of MCI outcome.

Varon D, Barker W, Loewenstein D, Greig M, Bohorquez A, Santos I, Shen Q, Harper M, Vallejo-Luces T, Duara R; Alzheimer's Disease Neuroimaging Initiative.

Int J Geriatr Psychiatry. 2015 Feb;30(2):192-200. doi: 10.1002/gps.4126. Epub 2014 May 12.

PMID:
24816477
14.

Long-Term Interrelationship between Brain Metabolism and Amyloid Deposition in Mild Cognitive Impairment.

Kemppainen N, Joutsa J, Johansson J, Scheinin NM, Någren K, Rokka J, Parkkola R, Rinne JO.

J Alzheimers Dis. 2015;48(1):123-33. doi: 10.3233/JAD-150190.

PMID:
26401934
15.

Whole-brain functional networks in cognitively normal, mild cognitive impairment, and Alzheimer's disease.

Seo EH, Lee DY, Lee JM, Park JS, Sohn BK, Lee DS, Choe YM, Woo JI.

PLoS One. 2013;8(1):e53922. doi: 10.1371/journal.pone.0053922. Epub 2013 Jan 15.

16.

Cognitive dysfunction in patients with very mild Alzheimer's disease and amnestic mild cognitive impairment showing hemispheric asymmetries of hypometabolism on ¹⁸F-FDG PET.

Murayama N, Ota K, Kasanuki K, Kondo D, Fujishiro H, Fukase Y, Tagaya H, Sato K, Iseki E.

Int J Geriatr Psychiatry. 2016 Jan;31(1):41-8. doi: 10.1002/gps.4287. Epub 2015 Mar 27.

PMID:
25820930
17.

Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET.

Shokouhi S, Claassen D, Kang H, Ding Z, Rogers B, Mishra A, Riddle WR; Alzheimer’s Disease Neuroimaging Initiative.

J Nucl Med. 2013 Sep;54(9):1564-9. doi: 10.2967/jnumed.112.116137. Epub 2013 Jul 17.

18.

Positron emission tomography metabolic correlates of apathy in Alzheimer disease.

Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL.

Arch Neurol. 2007 Jul;64(7):1015-20.

PMID:
17620493
19.

Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease.

Kadir A, Almkvist O, Forsberg A, Wall A, Engler H, Långström B, Nordberg A.

Neurobiol Aging. 2012 Jan;33(1):198.e1-14. doi: 10.1016/j.neurobiolaging.2010.06.015. Epub 2010 Aug 4.

PMID:
20688420
20.

Are apathy and depression independently associated with longitudinal trajectories of cortical atrophy in mild cognitive impairment?

Zahodne LB, Gongvatana A, Cohen RA, Ott BR, Tremont G; Alzheimer's Disease Neuroimaging Initiative.

Am J Geriatr Psychiatry. 2013 Nov;21(11):1098-106. doi: 10.1016/j.jagp.2013.01.043. Epub 2013 Apr 28.

Supplemental Content

Support Center